In this episode, Our Neuro Network's CEO, Neuroscience and Neurovascular Nurse Practitioner, and host Tiffany Hoke, DNP, RN, RNP, APRN-RX, AGACNP-BC, SCRN, CNRN addresses a complex and frequently asked question from patients: whether mast cell activation syndrome (MCAS) or chemical sensitivity is caused by jugular venous congestion and whether improving venous drainage could resolve symptoms.
The episode clarifies that MCAS is fundamentally a disorder of mast cell regulation, not a primary vascular condition. Mast cells are immune cells that release powerful mediators such as histamine, proteases, cytokines, and vascular endothelial growth factor (VEGF). These substances directly affect blood vessels by causing dilation, increased permeability, tissue swelling, and inflammatory changes. When mast cells degranulate near vascular structures, they can impair normal fluid dynamics and contribute to venous congestion, including within cerebral and cervical venous systems.
Importantly, the relationship between mast cell activation and venous congestion is bidirectional. Venous hypertension and impaired outflow can themselves trigger inflammation, recruit mast cells to vessel walls, and promote further degranulation. This creates a self-perpetuating cycle in which congestion activates mast cells, and mast cell mediators worsen vascular dysfunction. Emerging research also suggests mast cells may influence cerebrospinal fluid dynamics and brain-dura interfaces, highlighting their potential role in neurovascular symptoms.
The episode further explores why MCAS and chemical sensitivities often coexist with conditions involving connective tissue vulnerability, chronic inflammation, autonomic dysfunction, or metabolic stress.
Some individuals may have underlying genetic or metabolic factors that impair normal mast cell apoptosis (programmed cell death), allowing excessive mast cell accumulation and heightened reactivity to environmental triggers.
Crucially, improving jugular venous drainage alone is unlikely to resolve MCAS. While restoring outflow may reduce one source of inflammatory stress and improve symptoms in some patients, mast cell activation typically persists because the underlying immune dysregulation remains. Effective management therefore requires a comprehensive approach that addresses mast cell stabilization, trigger avoidance, and co-existing physiological stressors, rather than focusing solely on vascular mechanics.
This episode provides a science-based, patient-centered explanation intended to reduce confusion, validate lived experiences, and support informed discussions with healthcare providers about complex neuroimmune conditions.
Lastly, we discuss future episode topics, like sexual health and intimacy with cerebral venous congestion and intracranial pressure related conditions.
References
Bergan, J. J., Schmid-Schönbein, G. W., Smith, P. D., Nicolaides, A. N., Boisseau, M. R., & Eklof, B. (2006). Chronic venous disease. The New England Journal of Medicine, 355(5), 488–498. https://doi.org/10.1056/NEJMra055289
Chu, H. B., Yan, F., Zhao, J. H., et al. (2013). Assessment of the infiltration of inflammatory cells in the walls of thrombotic varicose veins. Angiology, 64(1), 69–72. https://doi.org/10.1177/0003319711435147
Kunder, C. A., St John, A. L., & Abraham, S. N. (2011). Mast cell modulation of the vascular and lymphatic endothelium. Blood, 118(20), 5383–5393. https://doi.org/10.1182/blood-2011-07-358432
Mamuladze, T., Zaninelli, T. H., Smyth, L. C. D., et al. (2025). Mast cells regulate the brain–dura interface and CSF dynamics. Cell. Advance online publication. https://doi.org/10.1016/j.cell.2025.06.046
Molderings, G. J. (2015). The genetic basis of mast cell activation disease—Looking through a glass darkly. Critical Reviews in Oncology/Hematology, 93(2), 75–89. https://doi.org/10.1016/j.critrevonc.2014.09.001
Molderings, G. J., Haenisch, B., Brettner, S., et al. (2016). Pharmacological treatment options for mast cell activation disease. Naunyn-Schmiedeberg’s Archives of Pharmacology, 389(7), 671–694. https://doi.org/10.1007/s00210-016-1247-1
Pappas, P. J., DeFouw, D. O., Venezio, L. M., et al. (1997). Morphometric assessment of the dermal microcirculation in patients with chronic venous insufficiency. Journal of Vascular Surgery, 26(5), 784–795. https://doi.org/10.1016/S0741-5214(97)70091-0
Piotin, A., Oulehri, W., Charles, A. L., et al. (2024). Oxidative stress and mitochondria are involved in anaphylaxis and mast cell degranulation: A systematic review. Antioxidants, 13(8), 920. https://doi.org/10.3390/antiox13080920
Schmid-Schönbein, G. W., Takase, S., & Bergan, J. J. (2001). New advances in the understanding of the pathophysiology of chronic venous insufficiency. Angiology, 52(Suppl 1), S27–S34. https://doi.org/10.1177/0003319701052001S04
Theoharides, T. C., Valent, P., & Akin, C. (2015). Mast cells, mastocytosis, and related disorders. The New England Journal of Medicine, 373(2), 163–172. https://doi.org/10.1056/NEJMra1409760
Valent, P., Akin, C., Nedoszytko, B., et al. (2020). Diagnosis, classification and management of mast cell activation syndromes (MCAS) in the era of personalized medicine. International Journal of Molecular Sciences, 21(23), 9030. https://doi.org/10.3390/ijms21239030
Weiler, C. R., Austen, K. F., Akin, C., et al. (2019). AAAAI mast cell disorders committee work group report: Mast cell activation syndrome (MCAS) diagnosis and management. Journal of Allergy and Clinical Immunology, 144(4), 883–896. https://doi.org/10.1016/j.jaci.2019.08.023
Note: Show transcripts are auto generated and may not be grammatically correct or accurate.
